Adicet Bio Future Growth

Future criteria checks 2/6

Adicet Bio is forecast to grow earnings and revenue by 6.7% and 79.7% per annum respectively while EPS is expected to grow by 9.5% per annum.

Key information

6.7%

Earnings growth rate

9.5%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	79.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	07 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:1IJA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4	-133	-69	-123	7
12/31/2025	3	-127	-81	-107	8
12/31/2024	N/A	-121	-100	-97	8
9/30/2024	N/A	-118	-93	-92	N/A
6/30/2024	N/A	-137	-93	-91	N/A
3/31/2024	N/A	-140	-95	-92	N/A
12/31/2023	N/A	-143	-98	-94	N/A
9/30/2023	N/A	-143	-100	-89	N/A
6/30/2023	N/A	-115	-98	-83	N/A
3/31/2023	N/A	-105	-89	-73	N/A
12/31/2022	25	-70	-62	-45	N/A
9/30/2022	30	-56	-53	-39	N/A
6/30/2022	34	-48	-49	-34	N/A
3/31/2022	39	-36	-47	-32	N/A
12/31/2021	10	-62	-64	-51	N/A
9/30/2021	10	-55	-61	-51	N/A
6/30/2021	9	-56	-52	-49	N/A
3/31/2021	12	-54	-50	-48	N/A
12/31/2020	18	-37	-43	-42	N/A
9/30/2020	14	-34	-37	-35	N/A
6/30/2020	4	-34	-36	-35	N/A
3/31/2020	0	-28	-30	-29	N/A
12/31/2019	1	-28	-29	-28	N/A
12/31/2018	8	-9	-19	-18	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1IJA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1IJA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1IJA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1IJA's revenue (79.7% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 1IJA's revenue (79.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1IJA's Return on Equity is forecast to be high in 3 years time

Adicet Bio Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Adicet Bio, Inc. Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

New minor risk - Market cap size

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

New minor risk - Market cap size

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Full year 2022 earnings released: US$1.70 loss per share (vs US$2.00 loss in FY 2021)

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Second quarter 2022 earnings released: US$0.56 loss per share (vs US$0.34 loss in 2Q 2021)

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.82 loss in 1Q 2021)

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

High number of new and inexperienced directors

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Adicet Bio Announces Positive Interim Clinical Data from First-Ever Allogeneic, Off-The-Shelf, Gamma Delta Car T Investigational Cell Therapy

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.48 loss in 2Q 2020)

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 3000E Growth Index

Senior VP, Chief Scientific & Operating Officer Stewart Abbot has left the company

First quarter 2021 earnings released: US$0.82 loss per share (vs US$0.26 loss in 1Q 2020)

Adicet Bio, Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$5.01 loss per share (vs US$1.63 loss in FY 2019)

Revenue beats expectations

Adicet Bio, Inc. Announces Initiation of its First-In-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Adicet Bio, Inc. Announces Board Changes

Director has left the company

Adicet Bio, Inc. Announces Resignation of Lloyd Klickstein as Chief Innovation Officer

New 90-day high: €13.70

New 90-day high: €12.10

New 90-day high: €11.96

Adicet Bio, Inc. Announces Appointment of Bastiano Sanna to Its Board of Directors

Adicet Bio, Inc. Announces the Appointment of Don Healey, as Chief Technology Officer, Effective October 26, 2020

Adicet Bio, Inc. Auditor Raises 'Going Concern' Doubt

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies